Aguilera G, Catt K J
Endocrinology. 1984 Jan;114(1):176-81. doi: 10.1210/endo-114-1-176.
The dopamine antagonist metoclopramide (MCP) has been shown to acutely stimulate aldosterone secretion in vivo. To determine whether a dopaminergic mechanism is involved in the regulation of aldosterone secretion, we examined the effect of minipump infusion of MCP (iv) and/or angiotensin II (AII;sc) upon plasma aldosterone, adrenal capsular AII receptors, and 18-hydroxylase activity in rats maintained on high sodium intake. During normal sodium intake, plasma aldosterone was elevated from 8.3 +/- 1.3 to 35.4 +/- 3.2 ng/dl after 2-day infusion of a nonnatriuretic dose of AII (25 ng/min) and to 15.0 +/- 1.8 ng/dl after the infusion of 1.2 micrograms/min MCP. AII receptors were unchanged by MCP infusion, and rose from 1014 +/- 98 to 1638 +/- 98 fmol/mg after AII infusion. During high sodium intake, the infusion of either AII or MCP alone produced no change in plasma aldosterone or AII receptors. However, after simultaneous infusion of AII and MCP, plasma aldosterone rose from 4.5 +/- 1.2 to 32.5 +/- 2.7 ng/dl, AII receptors increased from 969 +/- 35 to 1607 +/- 280 fmol/mg, and 18-hydroxylase activity, measured as the conversion of corticosterone to aldosterone by isolated mitochondria, rose from 29.5 +/- 1.67 to 40.6 +/- 2.9 pmol/mg . min. These adrenal responses induced by the combined treatment with AII and MCP were similar to the effects of AII infusion during normal sodium intake, indicating that MCP exerts a permissive action upon the trophic effects of AII on the adrenal cell during high sodium intake. These actions of MCP were completely abolished by the simultaneous infusion of dopamine (2 micrograms/min), suggesting that the effects of MCP on adrenal function are due to its dopaminergic antagonist properties. In collagenase-dispersed adrenal glomerulosa cells, only supraphysiological concentrations of dopamine in the incubation medium (10-100 microns) inhibited basal, AII-stimulated, and ACTH-stimulated aldosterone production, and these inhibitory effects were not reversed by high concentrations of MCP. Also, MCP itself inhibited both basal and stimulated aldosterone production. These results suggest that the stimulatory actions of MCP in vivo are exerted through liberation of other local regulators, rather than directly upon the adrenal glomerulosa cell. These findings have defined a mechanism by which the primary regulatory action of AII upon aldosterone secretion can be modulated during high sodium intake by dopaminergic inhibition of adrenal glomerulosa function.
多巴胺拮抗剂甲氧氯普胺(MCP)已被证明在体内能急性刺激醛固酮分泌。为了确定多巴胺能机制是否参与醛固酮分泌的调节,我们研究了在高钠摄入的大鼠中,微量泵输注MCP(静脉注射)和/或血管紧张素II(AII;皮下注射)对血浆醛固酮、肾上腺皮质AII受体和18 - 羟化酶活性的影响。在正常钠摄入期间,输注2天非利钠剂量的AII(25 ng/分钟)后,血浆醛固酮从8.3±1.3升高至35.4±3.2 ng/dl,输注1.2微克/分钟的MCP后升至15.0±1.8 ng/dl。输注MCP后AII受体无变化,输注AII后从1014±98升至1638±98 fmol/mg。在高钠摄入期间,单独输注AII或MCP对血浆醛固酮或AII受体均无影响。然而,同时输注AII和MCP后,血浆醛固酮从4.5±1.2升至32.5±2.7 ng/dl,AII受体从969±35增至1607±280 fmol/mg,以分离线粒体将皮质酮转化为醛固酮来衡量的18 - 羟化酶活性从29.5±1.67升至40.6±2.9 pmol/mg·分钟。AII和MCP联合治疗诱导的这些肾上腺反应与正常钠摄入期间输注AII的效果相似,表明在高钠摄入期间,MCP对AII对肾上腺细胞的营养作用发挥允许作用。同时输注多巴胺(2微克/分钟)可完全消除MCP的这些作用,提示MCP对肾上腺功能的影响归因于其多巴胺能拮抗剂特性。在胶原酶分散的肾上腺球状带细胞中,仅孵育培养基中高于生理浓度的多巴胺(10 - 100微摩尔)能抑制基础的、AII刺激的和促肾上腺皮质激素刺激的醛固酮生成,且这些抑制作用不能被高浓度的MCP逆转。此外,MCP本身也抑制基础的和刺激后的醛固酮生成。这些结果表明,MCP在体内的刺激作用是通过释放其他局部调节因子来发挥的,而不是直接作用于肾上腺球状带细胞。这些发现确定了一种机制,通过该机制,在高钠摄入期间,AII对醛固酮分泌的主要调节作用可通过多巴胺能抑制肾上腺球状带功能来调节。